Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | FABP3 | P05413 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522521 | 1.00 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL7352063 | 1.00 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL7352068 | 1.00 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL12592455 | 1.00 | KCNQ3 (0.53) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL12354198 | 0.96 | KCNQ3 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL838634 | 0.96 | KCNQ3 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL22492062 | 0.96 | KCNQ3 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL22492058 | 0.96 | KCNQ3 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL1752183 | 0.94 | SLC6A2 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD | |
| SCHEMBL1752024 | 0.94 | SLC6A2 (0.56) | KCNQ3KCNQ2SLC6A2SLC6A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | claimed |
| EP-2825538-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2825538-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Bristol-Myers Squibb Company (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8765767-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2013138687-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-19 | — | — | US | disclosed |
| US-8143405-B2 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| CN-102292319-A | Novel substituted octahydrocyclopenta(C)pyrrol-4-amines as calcium channel blockers | — | 2011-12-21 | — | — | CN | disclosed |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | disclosed |
| US-5734052-A | HYPOTENSIVE AGENTS, SEDATIVES, ANTISPASMODIC AGENTS AND VASODILATORS | MERRELL PHARMACEUTICALS INC. (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
| EP-0697020-A1 | 8-SUBSTITUTED XANTHINES AS SELECTIVE ADENOSINE RECEPTOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-21 | — | — | EP | disclosed |
| WO-1994026702-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994026744-A1 | 8-SUBSTITUTED XANTHINES AS SELECTIVE ADENOSINE RECEPTOR AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2C | KCNQ3 875/4885KCNQ2 721/4885SLC6A2 340/4885 |
| US-20100041667-A1 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | KCNQ3 2772/4885KCNQ2 1945/4885SLC6A2 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.